Share Name Share Symbol Market Type Share ISIN Share Description
Scapa Group Plc LSE:SCPA London Ordinary Share GB0007281198 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 315.00p 0 01:00:00
Bid Price Offer Price High Price Low Price Open Price
316.00p 317.50p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 291.50 28.80 15.40 20.5 487.1

Scapa (SCPA) Latest News

More Scapa News
Scapa Takeover Rumours

Scapa (SCPA) Share Charts

1 Year Scapa Chart

1 Year Scapa Chart

1 Month Scapa Chart

1 Month Scapa Chart

Intraday Scapa Chart

Intraday Scapa Chart

Scapa (SCPA) Discussions and Chat

Scapa Forums and Chat

Date Time Title Posts
22/5/201910:27Scapa onwards and upwards1,090
05/10/200615:18Scapa.......nobrainer or should I scarper?76
16/3/200613:43SCAPA upwards147

Add a New Thread

Scapa (SCPA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-05-22 16:15:00325.33936,9053,047,986.19O
2019-05-22 16:11:20317.502063.50O
2019-05-22 16:11:20316.971,8495,860.79O
View all Scapa trades in real-time

Scapa (SCPA) Top Chat Posts

Scapa Daily Update: Scapa Group Plc is listed in the Chemicals sector of the London Stock Exchange with ticker SCPA. The last closing price for Scapa was 315p.
Scapa Group Plc has a 4 week average price of 305p and a 12 week average price of 270.40p.
The 1 year high share price is 482p while the 1 year low share price is currently 270.40p.
There are currently 154,627,817 shares in issue and the average daily traded volume is 1,913,599 shares. The market capitalisation of Scapa Group Plc is £487,077,623.55.
hsduk101: Yep looking forward to this. Ill look out for any inside news closer to the date. See if any inside information is affecting the share price.
lammylover: £37m p.a. extra revenue is a 12.7% increase over last years FY results - significant jump in revenue from this one source alone. Very Positive. Hopefully push the share price back towards 500p again.. Rich
typo56: Interesting, Numis make no mention of the accident. Chosing to ignore or consider insignificant? They are, of course, the house broker! "Scapa Group's share price has fallen 18% since the company's trading statement last week and Numis says this makes the stock attractive and raises its recommendation to buy from add. The brokerage considers this an excellent entry point into a company that, since 2013, has delivered Ebita compound annual growth rate of 20%. Numis says further margin gains can be expected in the Industrials unit, as there is an increasingly favorable global GDP growth and construction outlook. The brokerage adds that the Healthcare division is well-positioned at a time of increased outsourcing, in a market that is reportedly growing at a rate of 9%. Shares are down 3.8% at 406 pence."
robow: Lovely write up here from Questor in the Daily Telegraph this morning. A 90-year-old manufacturer that was “at death’s door” a few years ago has transformed itself into a specialist, high-margin business with enviable returns on capital and cash generation – yet its valuation remains reasonable. Scapa originally made consumables for the paper industry. But it got into difficulty in the Nineties and sold that entire business to a German rival. “It was at death’s door at that point,” said Keith Ashworth-Lord, whose SDL UK Buffettology fund includes Aim-quoted Scapa as a top-10 holding. “Once it had sold the paper arm it was essentially left with a business that made industrial and electrical tapes, which are relatively unspecialised and low-margin products. Scapa at first did little to develop the tapes business and the group remained a bit of a mess.” All that changed in 2009 with the appointment as chief executive of Heejae Chae, previously of Volex, the cables group, said Ashworth-Lord. “Chae basically turned the business upside down,” the fund manager said. “He attacked the manufacturing base and started to take the products upmarket.” This involved a shift in the group’s focus from low-margin industrial tapes to more hi-tech areas such as wound dressings. “Then the company got even cleverer, making products that require ‘clean room’ technology, for example, and started to become a preferred partner to the likes of Johnson & Johnson and Smith & Nephew,” Ashworth-Lord said. The company’s transformation was largely achieved by the acquisition of three healthcare companies. “The areas it operates in now are more value-added – they involve providing solutions rather than just selling a product,” the fund manager said. “Scapa has always made double-digit margins in healthcare; they are currently about 16pc. “Meanwhile, margins in the legacy industrial business have also been improved: they are 11.5pc this year, up from about 3pc in 2011.” The industrial side still has the higher turnover but because of the difference in margins the healthcare business contributes more to the group’s profits. Scapa has improved efficiency in the industrials arm by consolidating its output into fewer factories, but has done so “really smartly”, Ashworth-Lord said. “It has maximised the value of redundant sites. For example, it demolished a factory in Switzerland, then cleared the site, got planning permission and sold it for housing. The result was a profit on the book value of the site. There is probably room for more consolidation of this type. The company does everything in a measured way.” He said the transformation of the company’s operations had a huge impact on its financial success, adding: “Returns on capital were once about 3pc; now they are 11pc, although returns on the capital most recently deployed are in the mid-20s. Cash conversion last year was 95pc. That sort of cash generation means that acquisitions can be funded out of cash flow.” Net debts are accordingly relatively modest at £16m, compared with net assets of about £100m. “That puts ‘gearing’; at 16pc – it’s not an over-leveraged balance sheet at all. All told, this is the kind of business I love.” The stock’s price-to-earnings ratio, based on last year’s “adjusted̶1; profits, is 32.1, but growth is 30pc-40pc annually: earnings per share were 3.6p in 2013, then 4.4p in 2014, 7.7p in 2015, 10.5p in 2016 and 14.8p last year. “It’s not dirt cheap, but you are paying a fair price for a quality business,” Ashworth-Lord said. “I have absolute faith in this company – the management knows its stuff, the business is really firing, I never have to worry about profit warnings. In the end it will probably be acquired but for now it is a core holding.” As an Aim-quoted trading business, Scapa should qualify for inheritance tax exemption if held for at least two years. Questor says: buy Ticker: SCPA Share price at close: 475.8p
robow: Numis upgrades Scapa on ‘significant’ potential Numis has upgraded chemicals group Scapa (SCPA) on prospects for ‘significant upside’ over the next two years. Analyst Paul Cuddon upgraded his recommendation from ‘hold’ to ‘add’ with a target price of 485p on the stock after the share price ‘softened since the publication of a strong set of interim results with trading profit up 22%’. ‘We see plenty of scope for further margin improvement,’ he said. ‘Mergers and acquisitions remain a key driver with two scalable platforms that can deliver both revenue and cost synergies. We see plenty of upside to mid-term forecasts and move back to “add” with around 10% upside to our target price.’ He added that ‘over the next two years we see far more significant upside to our 800p per share bull case’. The shares rose 2.1% to 441.5p yesterday.
grabster: Although the share price has multiplied a very impressive eightfold in 5 years, it can sometimes track sideways for up to a year at times. Hence definitely one for the longterm investor (2-3 years minimum) prepared to wait for the ongoing climb. I hold none at the moment but it remains on my watchlist to buy into sometime.
3rd eye: Scapa Group plc 27.1% Potential Upside Indicated by Berenberg Posted by: Katherine Hargreaves 15th April 2016 Scapa Group plc using EPIC/TICKER code LON:SCPA has had its stock rating noted as ‘Retains’; with the recommendation being set at ‘BUY’ this morning by analysts at Berenberg. Scapa Group plc are listed in the Basic Materials sector within AIM. Berenberg have set their target price at 300 GBX on its stock. This is indicating the analyst believes there is a potential upside of 27.1% from the opening price of 236 GBX. Over the last 30 and 90 trading days the company share price has increased 31.2933 points and increased 49 points respectively. Scapa Group plc LON:SCPA has a 50 day moving average of 204.10 GBX and a 200 day moving average of 202.42 GBX. The 1 year high share price is 245 GBX while the 52 week low is 156.73 GBX. There are currently 150,942,761 shares in issue with the average daily volume traded being 361,839. Market capitalisation for LON:SCPA is £363,394,697 GBP.
felix99: hope so! Looking good so far for one anyway if you believe the share price movement
cockneyrebel: I see Arden have upped their forecasts already to 2.7p eps for the year done and 3.6p eps for the coming year. £18m net cash and no debt means a share price of 30p with it strippped out. Reckon those forecasts will be tweaked up more at the results in May too imo. CR
spooky: Big volume and a rising share price,always a winning combination :-o)
Scapa share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190523 06:55:05